Circulating Gut Microbe-Derived Metabolites Are Associated with Hepatocellular Carcinoma.

UNLABELLED

Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide. The gut microbiome has been implicated in outcomes for HCC, and gut microbe-derived products may serve as potential non-invasive indices for early HCC detection. This study evaluated differences in plasma concentrations of gut microbiota-derived metabolites.

METHODS

Forty-one patients with HCC and 96 healthy controls were enrolled from surgical clinics at the Cleveland Clinic from 2016 to 2020. Gut microbiota-derived circulating metabolites detectable in plasma were compared between patients with HCC and healthy controls. Hierarchical clustering was performed for generating heatmaps based on circulating metabolite concentrations using ClustVis, with Euclidean and Ward settings and significant differences between metabolite concentrations were tested using a binary logistic regression model.

RESULTS

In patients with HCC, 25 (61%) had histologically confirmed cirrhosis. Trimethylamine (TMA)-related metabolites were found at higher concentrations in those with HCC, including choline ( < 0.001), betaine ( < 0.001), carnitine ( = 0.007), TMA ( < 0.001) and trimethylamine N-oxide (TMAO, < 0.001). Notably, concentrations of P-cresol glucuronide ( < 0.001), indole-lactic acid ( = 0.038), 5-hydroxyindoleacetic acid ( < 0.0001) and 4-hydroxyphenyllactic acid ( < 0.001) were also increased in those with HCC compared to healthy controls. Hierarchical clustering of the metabolite panel separated patients based on the presence of HCC ( < 0.001), but was not able to distinguish between patients with HCC based on the presence of cirrhosis ( = 0.42).

CONCLUSIONS

Gut microbiota-derived metabolites were differentially abundant in patients with HCC versus healthy controls. The observed perturbations of the TMAO pathway in HCC seem particularly promising as a target of future research and may have both diagnostic and therapeutic implications.